The bad news continued as Varian Medical Systems lost a major supply contract to rival Elekta in late July. Earlier in the month, the company reported preliminary results that showed sales of radiotherapy equipment were flat in the U.S. last quarter,
The bad news continued as Varian Medical Systems lost a major supply contract to rival Elekta in late July. Earlier in the month, the company reported preliminary results that showed sales of radiotherapy equipment were flat in the U.S. last quarter, sending its stock spiraling downward (SCAN 7/16/04).
News that Elekta had won a key three-year contract to supply Premier Purchasing Partners with radiation oncology systems knocked the company's stock down even further. Fearful of more bad news, investors sent the stock plummeting to hover just above the $60 mark in anticipation of final quarterly results after the market close July 29. The stock had cracked the $90 level in April.
On the up side, Varian introduced several new capabilities in July for its Eclipse 3D radiotherapy treatment planning software. The new software compensates automatically for variations in tissue thickness and has the ability to combine multiple targets within a single plan. Another enhancement supports inverse planning of IMRT treatments with linear accelerators from other suppliers.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.